PTO/SB/30 (05-03

Approved for use through 07/31/2006. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
o a collection of information unless it contains a valid OMB control number.

;	Request	
	for	
Continued	<b>Examination</b>	(RCE)
	<b>Fransmittal</b>	
ess to:		

Addre Mail Stop RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

the Paperwork Reduction Act of 1995, no persons are requir	ed to respond to a collection of informa	tion unless it contains a valid OMB control number.	
Request	Application Number	09/974,973	
	Filing Date	October 12, 2001	
for ntinued Examination (RCE) Transmittal o: RCE ioner for Patents	First Named Inventor	Paul D. Hanke	
to:	Art Unit	1652	
ioner for Patents	Examiner Name	E. Slobodyansky	
t 1450 ria, VA 22313-1450	Attorney Docket Number	031001	

This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application. Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2.

1.	Submission required under 37 CFR 1.114 Note: If the RCE is proper, any previously filed unentered amendments and amendments enclosed with the RCE will be entered in the order in which they were filed unless applicant instructs otherwise. If applicant does not wish to have any previously filed unentered amendment(s) entered, applicant must request non-entry of such							
	amendment(s).  Previously submitted. If a final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked.							
	Consider the arguments in the Appeal Brief or Rely Brief previously filed on  Other							
	b. Enclosed							
	i. Amendment/Reply iii. Information Disclosure Statement (IDS)							
	ii. Affidavit(s)/ Declaration(s) iv. Other							
2.	Miscellaneous							
	Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a							
	a period of months. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)							
	b. Other Do not enter amendments filed on January 23, 2004							
3.	Fees The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed.							
	The Director is hereby authorized to charge the following fees, or credit any overpayments, to  Deposit Account No							
	i. RCE fee required under 37 CFR 1.17(e)							
	ii. Extension of time fee (37 CFR 1.136 and 1.17)							
	iii. Other							
	b. Check in the amount of \$ 770.00enclosed							
	c. Payment by credit card (Form PTO-2038 enclosed)							
	WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.							
	SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED							

	Si	GNATURE OF	APPLICAN	I, JRI I OKNEY, OK	AGENI REQ	UIRED	
Name (Print/Type)	Bryan H. Opalko	72 11			Registration	n No. (Attorney/Agent)	40,751
Signature		WITT	424		Date	2-25-2	00 <i>4</i>
		CERT	CATE OF	MAILING OR TRAN	SMISSION	-	
	top RCE, Commissione					stage as first class mail itransmitted to the U.S. I	
Name (Print/Type)	_						
Signature					Date		
This collection of info	rmation is required by	37 CFR 1.114. T	he information	is required to obtain o	r retain a benefit	by the public which is to	file (and by the USP)

This collection of information is required by 37 CFR 1.114. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.114. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

00000049 09974973

03/03/2004 HVUUNG1

FB 2 5 2004 F

ERTIFICATE OF MAILING BY "EXPRESS MAIL" UNDER
37 CFR 1.10 - SEPARATE PAPER

ATTORNEY'S DOCKET NO.

031001

IN RE APPLICATION OF	<del></del>
Paul D. Hanke	
Serial No.	Filed
09/974,973	October 1 2, 2001
FOR FEEDBACK-RESISTAN CORYNEBACTERIUM	T PYRUVATE CARBOXYLASE GENE FROM
GRP. ART UNIT	EXAMINER
1652	E. Slobodyansky

"Express Mail" mailing label number

EV 256982662 US

Date of deposit:

February 25, 2004

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Bryan H. Opalko

(Typed or printed name of person mailing paper or fee)

(Signature of person mailing paper or for

PTO/SB/17 (10-03)

Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

FE	ETR	AN	SMI <sup>*</sup>	TTAL
	for	FY	2004	4

Effective 10/01/2003. Patent fees are subject to annual revision.

Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$) 770.00

TRADS

Complete if Known				
Application Number	09/974,973			
Filing Date	October 12, 2001			
First Named Inventor	Paul D. Hanke			
Examiner Name	E. Slobodyansky			
Art Unit	1652			
Attorney Docket No.	031001			

METHOD OF PAYMENT (check all that apply)	FEE CALCULATION (continued)					
X Check Credit card Money Other None	3. ADDITIONAL FEES					
X Deposit Account:	<u>Large Enti</u>	ity <sub> </sub>	Small	Entity		
Deposit Account:	Fee Fe			Fee	Fee Description	
Account   02 - 4553	Code (\$) 1051 13	· 1	Code 2051		Surcharge - late filing fee or oath	Fee Paid
Number Deposit Buchanan Ingersoll PC		- 1	2052		Surcharge - late provisional filing fee or	<del></del>
Account Name	1032 3	~	2002	20	cover sheet	<b></b>
The Director is authorized to: (check all that apply)	1053 13		1053		Non-English specification	
X Charge fee(s) indicated below X Credit any overpayments	1812 2,52	- 1	1812 2	,	For filing a request for ex parte reexamination	<b>—</b> —
X Charge any additional fee(s) or any underpayment of fee(s)	1804 92	20*	1804	920*	Requesting publication of SIR prior to Examiner action	
Charge fee(s) indicated below, except for the filing fee	1805 1,84	40*	1805	1,840*	Requesting publication of SIR after	
to the above-identified deposit account.				·	Examiner action	<b>  </b>
FEE CALCULATION		•	2251	55	Extension for reply within first month	<b></b>
1. BASIC FILING FEE			2252	210	Extension for reply within second month	$\vdash$
Large Entity Small Entity Fee Fee Fee Fee Description Fee Paid			2253		Extension for reply within third month	$\vdash$
Fee Fee Fee Fee Description Fee Paid Code (\$) Code (\$)	1254 1,48	80	2254	740	Extension for reply within fourth month	<b>  </b>
1001 770 2001 385 Utility filing fee	1255 2,0	10	2255	1,005	Extension for reply within fifth month	<del>                                     </del>
1002 340 2002 170 Design filing fee	1401 3	30	2401	165	Notice of Appeal	<u> </u>
1003 530 2003 265 Plant filing fee	1402 3	30	2402	165	Filing a brief in support of an appeal	<u> </u>
1004 770 2004 385 Reissue filing fee	1403 25	90	2403	145	Request for oral hearing	ļ
1005 160 2005 80 Provisional filing fee	1451 1,5°	10	1451	1,510	Petition to institute a public use proceeding	
SUBTOTAL (1) (\$)0.00	1452 1	10	2452	55	Petition to revive - unavoidable	
	1453 1,33	30	2453	665	Petition to revive - unintentional	
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE		30	2501	665	Utility issue fee (or reissue)	
Extra Claims below Fee Paid  Total Claims 20** = X	1502 4	80	2502	240	Design issue fee	
Independent	1503 64	40	2503	320	Plant issue fee	
Claims - 3** = X = 4 All Multiple Dependent	1460 13	30	1460	130	Petitions to the Commissioner	
	1807	50	1807	50	Processing fee under 37 CFR 1.17(q)	
Large Entity   Small Entity Fee Fee Fee Fee Fee Description	1806 18	80	1806		Submission of Information Disclosure Stmt	<b> </b>
Code (\$)	8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1202 18 2202 9 Claims in excess of 20	1809 7	70	2809	385	Filing a submission after final rejection	$\vdash$
1201 86 2201 43 Independent claims in excess of 3					(37 CFR 1.129(a))	<u> </u>
1203 290 2203 145 Multiple dependent claim, if not paid	1810 7	70	2810	385	For each additional invention to be	
1204 86 2204 43 ** Reissue independent claims over original patent	1801 7	70	2801	385	examined (37 CFR 1.129(b))  Request for Continued Examination (RCE)	770 0
1205 18 2205 9 ** Reissue claims in excess of 20		900	1802	900	•	770.00
and over original patent	1002 3	/ <sup>30</sup>	1002	300	of a design application	
SUBTOTAL (2) (\$) 0 . 0 0	Other fee	(spe	cify) _		·	
**or number previously paid, if greater; For Reissues, see above	*Reduced	d by f	Basic F	iling F	ee Paid SUBTOTAL (3) (\$) 7 7 (	0.00
		_				

SUBMITTED BY

Name (Print/Type)

Bryan H. Opalko

Registration No. (Complete (if applicable))

Telephone 412-562-1893


Signature

Date

2-25-2004

WARNING: Information of this form tray become public. Credit card information should not be included on this form rovide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



I hereby certify that this paper or fee is being deposited with the United States Postal Service Express Mail service under 37 C.F.R. § 1.10 on the date indicated above and is addressed to:

Commissioner for Patents P.O. Box 1450 Arlington, VA 22313-1450

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

PATENT APPLICATION

Paul D. Hanke

FEEDBACK-RESISTANT PYRUVATE

CARBOXYLASE GENE FROM

**CORYNEBACTERIUM** 

Serial No.: 09/974,973

Group Art Unit: 1652

Filed: October 12, 2001

Examiner: Slobodyansky, E.

Pittsburgh, Pennsylvania 15219

February 25, 2004

Mail Stop RCE Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

## AMENDMENT C AND REPLY TO FINAL OFFICE ACTION FILED AS SUBMISSIONS UNDER 37 C.F.R. § 1.114

Sir:

This is in response to the Final Office Action, mailed November 25, 2003 in connection with the above-identified application, having a statutory period for response set to expire on February 25, 2004. In response, Applicant is filing herewith a Request for Continued Examination Under 37 C.F.R. § 1.114.

Applicant respectfully requests that the amendments contained in the "Amendment B and Reply to Final Official Action under 37 C.F.R. § 1.116", filed on January 23, 2004 and refused entry in an Advisory Action mailed on February 11, 2004, **not** be entered for the above-identified application.

Applicant further requests that the amendments included in this Amendment C be entered.

The Examiner's objections and rejections have been carefully considered, and in view of the following remarks and amendments, reconsideration and early allowance of all pending claims is respectfully requested. Please amend this application as follows:

Amendments to the Specification begin on page 3 of this Amendment.

Amendments to the Claims are reflected in the Listing of Claims which begins on page 4 of this Amendment.

Amendments to the Drawings begin on page 8 of this Amendment and include both attached replacement sheets and annotated sheets showing changes.

Remarks/Arguments begin on page 9 of this Amendment.

An **Appendix** including amended drawing figures is attached following page 15 of this Amendment.